Dr. Simoes carried out many of the studies that provide the scientific foundation for the WHO Integrated Case Management of Childhood Illness. He has successfully collaborated with researchers throughout the world, as well as in Colorado on respiratory infections. He has conducted numerous collaborative studies on the epidemiology, prevention and treatment and pathogenesis of respiratory infections (primarily respiratory syncytial virus, influenza and Streptococcus pneumonia) in Europe, India, Philippines, Indonesia, Japan, Kenya and Sourh Africa most recently. His work with RSV over the past 20 years has in part led to the development and licensure of two products for RSV prophylaxis (RSV –IGIV, and palivizumab). These studies carried out in premature infants have assessed the effects of prevention of RSV onshore and long term respiratory morbidity. He has a broad background in infectious diseases with specific training and expertise in epidemiology and molecular virology.

Dr. Simoes carried out many of the studies that provide the scientific foundation for the WHO Integrated Case Management of Childhood Illness. He has successfully collaborated with researchers throughout the world, as well as in Colorado on respiratory infections. He has conducted numerous collaborative studies on the epidemiology, prevention and treatment and pathogenesis of respiratory infections (primarily respiratory syncytial virus, influenza and Streptococcus pneumonia) in Europe, India, Philippines, Indonesia, Japan, Kenya and Sourh Africa most recently. His work with RSV over the past 20 years has in part led to the development and licensure of two products for RSV prophylaxis (RSV –IGIV, and palivizumab). These studies carried out in premature infants have assessed the effects of prevention of RSV onshore and long term respiratory morbidity. He has a broad background in infectious diseases with specific training and expertise in epidemiology and molecular virology.

Dr. Simoes carried out many of the studies that provide the scientific foundation for the WHO Integrated Case Management of Childhood Illness. He has successfully collaborated with researchers throughout the world, as well as in Colorado on respiratory infections. He has conducted numerous collaborative studies on the epidemiology, prevention and treatment and pathogenesis of respiratory infections (primarily respiratory syncytial virus, influenza and Streptococcus pneumonia) in Europe, India, Philippines, Indonesia, Japan, Kenya and Sourh Africa most recently. His work with RSV over the past 20 years has in part led to the development and licensure of two products for RSV prophylaxis (RSV –IGIV, and palivizumab). These studies carried out in premature infants have assessed the effects of prevention of RSV onshore and long term respiratory morbidity. He has a broad background in infectious diseases with specific training and expertise in epidemiology and molecular virology.

Dr. Simoes carried out many of the studies that provide the scientific foundation for the WHO Integrated Case Management of Childhood Illness. He has successfully collaborated with researchers throughout the world, as well as in Colorado on respiratory infections. He has conducted numerous collaborative studies on the epidemiology, prevention and treatment and pathogenesis of respiratory infections (primarily respiratory syncytial virus, influenza and Streptococcus pneumonia) in Europe, India, Philippines, Indonesia, Japan, Kenya and Sourh Africa most recently. His work with RSV over the past 20 years has in part led to the development and licensure of two products for RSV prophylaxis (RSV –IGIV, and palivizumab). These studies carried out in premature infants have assessed the effects of prevention of RSV onshore and long term respiratory morbidity. He has a broad background in infectious diseases with specific training and expertise in epidemiology and molecular virology.